Alpha 0261
Alternative Names: Alpha-0261Latest Information Update: 17 Dec 2025
At a glance
- Originator AlphaMol
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis
Most Recent Events
- 21 Jul 2025 Phase-I clinical trials in Atopic dermatitis (In volunteers) in China (PO) (NCT07279636) (CTR20253320)